WallStSmart

Bloom Energy Corp (BE)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

West Pharmaceutical Services Inc generates 32% more annual revenue ($3.22B vs $2.45B). WST leads profitability with a 16.9% profit margin vs 0.3%. BE appears more attractively valued with a PEG of 1.53. WST earns a higher WallStSmart Score of 65/100 (C+).

BE

Hold

40

out of 100

Grade: D

Growth: 6.7Profit: 5.0Value: 4.7Quality: 5.3
Piotroski: 3/9Altman Z: -0.52

WST

Buy

65

out of 100

Grade: C+

Growth: 7.3Profit: 8.0Value: 2.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BE.

WSTSignificantly Overvalued (-32.4%)

Margin of Safety

-32.4%

Fair Value

$185.95

Current Price

$322.30

$136.35 premium

UndervaluedFair: $185.95Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BE2 strengths · Avg: 9.5/10
Revenue GrowthGrowth
130.4%10/10

Revenue surging 130.4% year-over-year

Market CapQuality
$73.57B9/10

Large-cap with strong market position

WST4 strengths · Avg: 9.0/10
EPS GrowthGrowth
56.1%10/10

Earnings expanding 56.1% YoY

Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.7%8/10

Strong operational efficiency at 21.7%

Revenue GrowthGrowth
21.0%8/10

Revenue surging 21.0% year-over-year

Areas to Watch

BE4 concerns · Avg: 3.3/10
PEG RatioValuation
1.534/10

Expensive relative to growth rate

Return on EquityProfitability
1.3%3/10

ROE of 1.3% — below average capital efficiency

Profit MarginProfitability
0.3%3/10

0.3% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

WST2 concerns · Avg: 2.0/10
PEG RatioValuation
3.142/10

Expensive relative to growth rate

P/E RatioValuation
43.5x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : BE

The strongest argument for BE centers on Revenue Growth, Market Cap. Revenue growth of 130.4% demonstrates continued momentum.

Bull Case : WST

The strongest argument for WST centers on EPS Growth, Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.9% and operating margin at 21.7%. Revenue growth of 21.0% demonstrates continued momentum.

Bear Case : BE

The primary concerns for BE are PEG Ratio, Return on Equity, Profit Margin. Thin 0.3% margins leave little buffer for downturns.

Bear Case : WST

The primary concerns for WST are PEG Ratio, P/E Ratio. A P/E of 43.5x leaves little room for execution misses.

Key Dynamics to Monitor

BE profiles as a hypergrowth stock while WST is a growth play — different risk/reward profiles.

BE carries more volatility with a beta of 3.83 — expect wider price swings.

BE is growing revenue faster at 130.4% — sustainability is the question.

BE generates stronger free cash flow (48M), providing more financial flexibility.

Bottom Line

WST scores higher overall (65/100 vs 40/100), backed by strong 16.9% margins and 21.0% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Bloom Energy Corp

INDUSTRIALS · ELECTRICAL EQUIPMENT & PARTS · USA

Bloom Energy Corporation designs, manufactures and sells solid oxide fuel cell systems for on-site power generation in the United States, Japan, China, India, and the Republic of Korea. The company is headquartered in San Jose, California.

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?